Zura Bio’s Strategic Positioning and Promising Asset Portfolio: A Buy Recommendation by Analyst Faisal Khurshid
Faisal Khurshid, an analyst from Leerink Partners, has initiated a new Buy rating on Zura Bio (ZURA). Faisal Khurshid has given his Buy rating ...
Pharma takes aim at a wily foe — the Epstein-Barr virus
Many studies have revealed links between EBV and conditions like MS, an autoimmune disease affecting the brain and spinal cord. EBV is also suspected to play a role in autoimmune diseases such as ...
Immunic to Participate in Industry, Scientific and Investor Conferences in November
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...
bovnews3d
Immunic Inc (IMUX) Stock: More Strategic Than Meets the Eye
On Friday, Immunic Inc (IMUX) stock saw a decline, ending the day at $1.19 which represents a decrease of $-0.02 or -1.65% from the prior close of $1.21. The stock opened at $1.21 and touched a low of ...
bovnews6d
Immunic Inc (IMUX) Stock Settles at $1.31: What’s Contributing to This Price Point?
Leerink Partners has recently resumed Immunic Inc (IMUX) stock to Outperform rating, as announced on September 9, 2024, according to Finviz. Earlier, on August 27, 2024, B. Riley Securities had ...